We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Mutations Associated to Antibiotic-Resistant Helicobacter pylori : It Is Time to Validate Sequencing Observations.
- Authors
Pichon, Maxime; Luzarraga, Victor; Burucoa, Christophe
- Abstract
I H. pylori i , a Gram-negative microaerophilic microorganism, is the only bacterial pathogen classified as a Class I carcinogen, due to its association, since its initial discovery, with severe gastric disease (including gastritis, gastric ulcers, gastric adenocarcinoma, or lymphoid tissue lymphoma associated with mucosa), and its extraordinary overall prevalence, estimated at 4.4 billion patients worldwide [[1]]. Most infected patients receive empirical treatment with a proton pump inhibitor combined with dual antibiotics (tetracycline-metronidazole) or even triple antibiotics (amoxicillin-clarithromycin-metronidazole) combined with bismuth salts or dual antibiotics (amoxicillin-clarithromycin) without bismuth salts. 29990487 5 Vital J.S., Tanoeiro L., Lopes-Oliveira R., Vale F.F. Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance from Helicobacter Pylori Next Generation Sequencing Data.
- Subjects
HELICOBACTER pylori; GENETIC mutation
- Publication
Journal of Clinical Medicine, 2022, Vol 11, Issue 15, p4293
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm11154293